At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
crisaborole ointment +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Local Tolerability of Crisaborole Ointment, 2%, in Adult Participants With Stasis Dermatitis Without Active Skin Ulceration
In Brief
A Phase 2 clinical trial evaluating crisaborole ointment and vehicle ointment for Stasis Dermatitis. Completed, enrolled 66 participants across 4 sites.
Detailed Summary
This is a Phase 2a, randomized, double blind, vehicle controlled, parallel group, proof of concept study that will include participants with stasis dermatitis without active skin ulceration, who will receive crisaborole ointment 2% or vehicle twice daily for 6 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStasis Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartJun 2020
Primary CompletionOct 2021
TodayJul 2026
First PostedSep 16, 2019
Enrollment StartJun 26, 2020
Primary CompletionOct 19, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.8 years ago
Interventions
crisaborole ointmentdrug
crisaborole ointment
vehicle ointmentother
vehicle ointment